Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mt. Sinai researchers report that aspirin reduces risk of first heart attack by one-third

23.09.2003


Aspirin reduces the risk of a first heart attack by 32 percent, according to a report by researchers at Mount Sinai Medical Center & Miami Heart Institute (MSMC-MHI) published in the current issue of Archives of Internal Medicine. The paper, which is based on a meta-analysis of five major randomized clinical trials (55,580 participants, 11,466 women) in primary prevention, also found that aspirin reduces the combined risk of heart attack, stroke and vascular death by 15 percent.



Charles H. Hennekens, M.D., Co-Director of Cardiovascular Research at MSMC-MHI, and Professor of Medicine & Epidemiology and Public Health at the University of Miami School of Medicine was the first to demonstrate the benefit of aspirin in reducing the risk of a first heart attack in a landmark Physicians’ Health Study (PHS), which was published in 1988 in the New England Journal of Medicine. Under his direction, Rachel S. Eidelman, M.D., a cardiology fellow at MSMC-MHI, performed the latest meta-analysis.

The findings strongly support the treatment guidelines issued by the American Heart Association (AHA), which recommends the use of aspirin for all men and women whose 10-year risks of a first coronary event are 10 percent or greater. The U.S. Preventive Services Task Force (USPSTF) released similar guidelines earlier in 2002, urging all healthcare providers to consider the use of aspirin in all apparently healthy men and women with a 6 percent or greater 10-year risk of a coronary event.


"The individual trials and their meta-analysis support the AHA and USPSTF guidelines, which note that the benefits of long-term aspirin use are likely to outweigh any risks for these individuals," Hennekens said. "The more widespread and appropriate use of aspirin in primary prevention could avoid hundreds of thousands of first heart attacks and important vascular events each year in the U.S."

The aspirin component of Dr. Hennekens trial, the PHS, was terminated early on January 25, 1988 based on the unanimous recommendations of the Data and Safety Monitoring Board, due primarily to a statistically extreme 44 percent reduction in risk of a first heart attack among those assigned at random to aspirin. There have been four primary prevention trials published since then, three of which showed similar positive findings for aspirin.

"We found that the current totality of evidence strongly supports our initial findings from the Physicians’ Health Study that aspirin significantly reduces the risk of a first heart attack in apparently healthy individuals," Hennekens added. "This data, along with the findings that aspirin reduces the risk of death by 23 percent if given during a heart attack and by 15 percent in a wide range of people who have survived prior cardiovascular events, demonstrate the need for wider utilization of aspirin."

"Yet despite the clearly demonstrated cardio-protective benefits of aspirin, this medication remains alarmingly underutilized among survivors of prior events, those having a heart attack and apparently healthy men and women, whose 10-year risk is 10 percent or more," Hennekens continued. "We hope the latest findings result in greater awareness on the part of healthcare providers and the general public and motivate increased aspirin utilization, which could result in significant reductions of premature cardiovascular deaths and first heart attacks."

Coronary heart disease is the single leading cause of death in the United States, accounting for more than 500,000 deaths annually. Approximately 80 percent of deaths from coronary heart disease in people under age 65 occur during the first heart attack.



Mount Sinai & Miami Heart’s Cardiovascular Center of Excellence is committed to being a leader in the prevention, diagnosis and treatment of heart disease. The medical center is the largest cardiac services provider in South Florida, conducting approximately 1,300 open heart procedures and approximately 7,400 diagnostic and therapeutic cardiac catheterizations annually.

For a physician referral, please call (305) 674-2273

Katie Cline | EurekAlert!

More articles from Health and Medicine:

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>